A Phase II prospective, single-centre trial comparing the diagnostic performance of TLX250-CDx PET/CT[3] in patients with recurrent clear cell renal cell carcinoma (ccRCC) after surgery.

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Oct 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

10 Oct 2024 New trial record
04 Oct 2024 According to a Telix Pharmaceuticals media release, Professor Brian Shuch is the principal investigator on the CA-NINE trial.
04 Oct 2024 According to a Telix Pharmaceuticals media release, First patient has been dosed in Phase II 'CA-NINE' Trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com